LENSAR, Inc. Stock

Equities

LNSR

US52634L1089

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
3.26 USD +2.52% Intraday chart for LENSAR, Inc. +6.54% -7.12%
Sales 2024 * 51.3M Sales 2025 * 62.7M Capitalization 37.15M
Net income 2024 * -11M Net income 2025 * -9M EV / Sales 2024 * 0.72 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.59 x
P/E ratio 2024 *
-3.15 x
P/E ratio 2025 *
-3.84 x
Employees 130
Yield 2024 *
-
Yield 2025 *
-
Free-Float 82.53%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.52%
1 week+6.54%
Current month-4.03%
1 month-7.12%
3 months-4.12%
6 months+49.54%
Current year-7.12%
More quotes
1 week
3.10
Extreme 3.1
3.33
1 month
2.67
Extreme 2.67
3.92
Current year
2.67
Extreme 2.67
5.30
1 year
1.80
Extreme 1.8
5.30
3 years
1.80
Extreme 1.8
8.98
5 years
1.80
Extreme 1.8
12.71
10 years
1.80
Extreme 1.8
12.71
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 10-07-31
Director of Finance/CFO 56 20-04-30
Chief Operating Officer 52 07-12-31
Members of the board TitleAgeSince
Chief Executive Officer 68 10-07-31
Director/Board Member 54 23-05-24
Director/Board Member 76 18-02-01
More insiders
Date Price Change Volume
24-04-24 3.26 +2.52% 8,334
24-04-23 3.18 -2.15% 13,632
24-04-22 3.25 +0.62% 19,344
24-04-19 3.23 +2.87% 7,010
24-04-18 3.14 +2.61% 38,851

Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT

More quotes
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its product portfolio consists of the LENSAR Laser System and ALLY Adaptive Cataract Treatment System (ALLY System) and its associated consumable components. The system incorporates a range of technologies designed to assist the surgeon in obtaining visual outcomes. The consumable portion of the system consists of a disposable patient interface device kit. The ALLY System is designed to combine its femtosecond laser technology features with enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. Its system is used across surgeons, hospital outpatient surgical facilities and ambulatory surgery centers.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.26 USD
Average target price
8 USD
Spread / Average Target
+145.40%
Consensus